Overview
AUTL market data
Price History
AUTL price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.08 Diluted earnings per share over the trailing twelve months.
- Beta
- 2.17 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -312.0% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1.18 – $2.50 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $564.3M · P/B 2.94 · P/S 6.09.
Company News
Autolus Therapeutics shares are trading higher after the company reported better-than-expected Q2 financial results.Benzinga · Aug 11, 2026, 4:57 PM
8-K filing — Autolus Therapeutics plc (AUTL)SEC EDGAR · Aug 11, 2026, 11:33 AM
Autolus Therapeutics Affirms FY2026 Sales Guidance of $140.000M-$150.000M vs $136.669M EstBenzinga · Aug 11, 2026, 11:01 AM
Autolus Therapeutics Q2 EPS $(0.15) Beats $(0.23) Estimate, Sales $45.689M Beat $34.016M EstimateBenzinga · Aug 11, 2026, 11:00 AM
HC Wainwright & Co. Reiterates Buy on Autolus Therapeutics, Maintains $10 Price TargetBenzinga · Aug 3, 2026, 5:25 PM
CNH Industrial Posts Upbeat Q2 Earnings, Joins Autolus Therapeutics, Bowhead Specialty Holdings And Other Big Stocks Moving Higher On MondayBenzinga · Aug 3, 2026, 2:00 PM
Autolus Therapeutics shares are trading higher after the company reported preliminary Q2 AUCATZYL sales results. Also, the company raised its FY26 sales guidance.Benzinga · Aug 3, 2026, 12:52 PM
Autolus Therapeutics Reports Preliminary Q2 AUCATZYL Sales Of ~$45M; Raises FY2026 Sales Guidance From $120M-$135M To $140M-$150MBenzinga · Aug 3, 2026, 11:20 AM
Autolus Therapeutics to Participate in Upcoming Investor ConferencesGlobenewswire Inc · May 27, 2026, 11:15 AM
Toyo Posts Upbeat Q1 Earnings, Joins Brady, Dominion Energy And Other Big Stocks Moving Higher On MondayBenzinga · May 18, 2026, 4:35 PM